FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	•		
STATEMENT (	OF CHANGES I	N BENEFICIAL	<b>OWNERSHIP</b>

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average b	urden							
- 1	hours por rosponso:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person*  Eydelman Mikhail						2. Issuer Name and Ticker or Trading Symbol  Vaxcyte, Inc. [ PCVX ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner						
(Last)	КСҮТЕ,	(Firs	′	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/29/2024							give title	Other below) SEL & CORP				
825 INDUSTRIAL ROAD, SUITE 300							4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN CARLOS CA 94070							X Form filed by One Reporting Person Form filed by More than One Reporting Person												
(City) (State) (Zip)					Ru	Rule 10b5-1(c) Transaction Indication													
					X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
			Та	ble I - N	on-Der	ivative	Securities Ac	quire	d, Di	isposed of	, or Be	neficially	Owned						
Date			2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership						
								Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)			
Common Stock				02/29	/2024		A		10,500(1)	A	\$ <mark>0</mark>	31,210		D					
Common Stock 03				03/01	/2024		M		1,667	A	\$21.41	32,877		D					
Common Stock 03/01/2					/2024		S <sup>(2)</sup>		519	D	\$73.025 <sup>(3</sup>	32,	358	D					
Common Stock 03/01/2						/2024		S <sup>(2)</sup>		703	D	\$73.59(4)	31,	655	D				
Common Stock 03/01/2					/2024		S <sup>(2)</sup>		445	D	\$74.771(5	31,	210	D					
Common Stock 03/02/2						/2024		F		613(6)	D	\$71.55	30,	597	D				
				Table II			Securities Acq calls, warrants						Owned						
1. Title of Derivative Conversion Or Exercise (Instr. 3)  1. Title of Derivative Security (Instr. 3)  2.		n Date,	4. Transacti Code (Ins 8)		6. Date Exercisa Expiration Date (Month/Day/Yea		Date	of Secur Underlyi	ng re Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following	Ownershi Form: Direct (D) or Indirec	Beneficial Ownership t (Instr. 4)						

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$73.82	02/29/2024		A		50,000		(7)	02/28/2034	Common Stock	50,000	\$0	50,000	D	
Stock Option (right to buy)	\$21.41	03/01/2024		M			1,667	(8)	05/08/2032	Common Stock	1,667	\$0	189,999	D	

## Explanation of Responses:

- 1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
- 2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
- 3. The price reported is a weighted-average price. The shares were sold at prices ranging from \$72.39 to \$73.325. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. The price reported is a weighted-average price. The shares were sold at prices ranging from \$73.42 to \$73.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 5. The price reported is a weighted-average price. The shares were sold at prices ranging from \$74.55 to \$74.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 6. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
- 7. 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
- 8. 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

/s/ Ron A. Metzger, Attorneyin-Fact

03/04/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.